COMT Inhibitors in the Treatment of Parkinson's Disease

E. V. Encarnacion; R. A. Hauser

doi:10.1016/B978-0-12-374105-9.00315-4

COMT Inhibitors in the Treatment of Parkinson's Disease

E. V. Encarnacion, R. A. Hauser

Neurology & Neurotherapeutics

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations

Abstract

Levodopa continues to be the most efficacious dopaminergic agent in the treatment of parkinsonian motor symptoms. Its long term administration, however, combined with the progressive loss of cells in advanced disease, is associated with the wearing 'off' episodes and dyskinesia. COMT inhibition through Tolcapone and Entacapone may alleviate these motor complications.

Original language	English (US)
Title of host publication	Encyclopedia of Movement Disorders
Publisher	Elsevier Inc.
Pages	246-249
Number of pages	4
ISBN (Electronic)	9780123741059
ISBN (Print)	9780123741011
DOIs	https://doi.org/10.1016/B978-0-12-374105-9.00315-4
State	Published - Jan 1 2010

Keywords

COMT
Dyskinesia
Entacapone
Fluctuation
Levodopa
Mechanism
Parkinson's disease
Stalevo
Tolcapone
Treatment

ASJC Scopus subject areas

General Medicine
General Neuroscience

Access to Document

10.1016/B978-0-12-374105-9.00315-4

Cite this

@inbook{b1920a2d678744da845b5aad17a21797,

title = "COMT Inhibitors in the Treatment of Parkinson's Disease",

abstract = "Levodopa continues to be the most efficacious dopaminergic agent in the treatment of parkinsonian motor symptoms. Its long term administration, however, combined with the progressive loss of cells in advanced disease, is associated with the wearing 'off' episodes and dyskinesia. COMT inhibition through Tolcapone and Entacapone may alleviate these motor complications.",

keywords = "COMT, Dyskinesia, Entacapone, Fluctuation, Levodopa, Mechanism, Parkinson's disease, Stalevo, Tolcapone, Treatment",

author = "Encarnacion, {E. V.} and Hauser, {R. A.}",

year = "2010",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-374105-9.00315-4",

language = "English (US)",

isbn = "9780123741011",

pages = "246--249",

booktitle = "Encyclopedia of Movement Disorders",

publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - COMT Inhibitors in the Treatment of Parkinson's Disease

AU - Encarnacion, E. V.

AU - Hauser, R. A.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Levodopa continues to be the most efficacious dopaminergic agent in the treatment of parkinsonian motor symptoms. Its long term administration, however, combined with the progressive loss of cells in advanced disease, is associated with the wearing 'off' episodes and dyskinesia. COMT inhibition through Tolcapone and Entacapone may alleviate these motor complications.

AB - Levodopa continues to be the most efficacious dopaminergic agent in the treatment of parkinsonian motor symptoms. Its long term administration, however, combined with the progressive loss of cells in advanced disease, is associated with the wearing 'off' episodes and dyskinesia. COMT inhibition through Tolcapone and Entacapone may alleviate these motor complications.

KW - COMT

KW - Dyskinesia

KW - Entacapone

KW - Fluctuation

KW - Levodopa

KW - Mechanism

KW - Parkinson's disease

KW - Stalevo

KW - Tolcapone

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85069869654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069869654&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-374105-9.00315-4

DO - 10.1016/B978-0-12-374105-9.00315-4

M3 - Chapter

AN - SCOPUS:85069869654

SN - 9780123741011

SP - 246

EP - 249

BT - Encyclopedia of Movement Disorders

PB - Elsevier Inc.

ER -

COMT Inhibitors in the Treatment of Parkinson's Disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this